Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: miltefosine
Trade Name: IMPAVIDO
Date Designated: 10/10/2006
Orphan Designation: Treatment of leishmaniasis.
Orphan Designation Status: Designated/Approved
Knight Therapeutics (USA)
Corporation Trust Center
1209 Orange Street
Wilmington, Delaware 19801
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: miltefosine
Trade Name: IMPAVIDO
Marketing Approval Date: 03/19/2014
Approved Labeled Indication: Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis.
Exclusivity End Date: 03/19/2021 
Exclusivity Protected Indication* :  Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis.
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-